These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28928137)

  • 1. Recovery of CYP3A Phenotype after Kidney Transplantation.
    Hole K; Størset E; Olastuen A; Haslemo T; Kro GB; Midtvedt K; Åsberg A; Molden E
    Drug Metab Dispos; 2017 Dec; 45(12):1260-1265. PubMed ID: 28928137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.
    Størset E; Hole K; Midtvedt K; Bergan S; Molden E; Åsberg A
    Br J Clin Pharmacol; 2017 Jul; 83(7):1457-1465. PubMed ID: 28146606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
    Vanhove T; Hasan M; Annaert P; Oswald S; Kuypers DRJ
    Br J Clin Pharmacol; 2017 Nov; 83(11):2406-2415. PubMed ID: 28603840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients.
    Suzuki Y; Muraya N; Fujioka T; Sato F; Tanaka R; Matsumoto K; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
    Pharmacol Rep; 2019 Apr; 71(2):276-281. PubMed ID: 30826567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.
    Hole K; Heiberg PL; Gjestad C; Mehus LL; Rø Ø; Molden E
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00430. PubMed ID: 30214813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration.
    Hole K; Gjestad C; Heitmann KM; Haslemo T; Molden E; Bremer S
    Eur J Clin Pharmacol; 2017 Mar; 73(3):317-324. PubMed ID: 27975131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.
    Suzuki Y; Fujioka T; Sato F; Matsumoto K; Muraya N; Tanaka R; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
    Br J Clin Pharmacol; 2015 Dec; 80(6):1421-8. PubMed ID: 26773964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.
    Suzuki Y; Itoh H; Fujioka T; Sato F; Kawasaki K; Sato Y; Sato Y; Ohno K; Mimata H; Kishino S
    Drug Metab Dispos; 2014 Jan; 42(1):105-10. PubMed ID: 24135442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?
    Gjestad C; Huynh DK; Haslemo T; Molden E
    Br J Clin Pharmacol; 2016 Feb; 81(2):269-76. PubMed ID: 26574235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation.
    Suzuki Y; Itoh H; Sato F; Kawasaki K; Sato Y; Fujioka T; Sato Y; Ohno K; Mimata H; Kishino S
    J Lipid Res; 2013 Sep; 54(9):2568-72. PubMed ID: 23833241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
    Gjestad C; Haslemo T; Andreassen OA; Molden E
    Br J Clin Pharmacol; 2017 Nov; 83(11):2398-2405. PubMed ID: 28585378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.
    Eide Kvitne K; Hole K; Krogstad V; Wollmann BM; Wegler C; Johnson LK; Hertel JK; Artursson P; Karlsson C; Andersson S; Andersson TB; Sandbu R; Hjelmesæth J; Skovlund E; Christensen H; Jansson-Löfmark R; Åsberg A; Molden E; Robertsen I
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1289-1299. PubMed ID: 35648149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β-Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma.
    Hirai K; Kimura T; Suzuki Y; Shimoshikiryo T; Shirai T; Itoh K
    Clin Pharmacol Ther; 2024 Jul; 116(1):147-154. PubMed ID: 38482940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Grapefruit Juice Intake on Serum Level of the Endogenous CYP3A4 Metabolite 4β-Hydroxycholesterol-an Interaction Study in Healthy Volunteers.
    Gjestad C; Hole K; Haslemo T; Diczfalusy U; Molden E
    AAPS J; 2019 Apr; 21(4):58. PubMed ID: 31020430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
    Diczfalusy U; Nylén H; Elander P; Bertilsson L
    Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
    Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
    Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
    Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.
    Kim AH; Yoon S; Lee Y; Lee J; Bae E; Lee H; Kim DK; Lee S; Yu KS; Jang IJ; Cho JY
    J Korean Med Sci; 2018 Dec; 33(53):e298. PubMed ID: 30595680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.